Alexion

Alexion is a global biopharmaceutical company dedicated to developing and delivering life-changing therapies for patients with rare diseases. Founded in 1992, the company has established itself as a leader in the field of complement inhibition, focusing on innovative treatments that address unmet medical needs.

With a commitment to scientific excellence, Alexion invests heavily in research and development, striving to bring new therapies to market that can significantly improve the quality of life for patients. The company’s flagship product, Soliris, has transformed the treatment landscape for conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS).

In addition to its core focus on rare diseases, Alexion is expanding its portfolio to include therapies for other serious conditions, including neurology and hematology. The company operates globally, with a strong presence in North America, Europe, and Asia, ensuring that its innovative treatments reach patients around the world.

Alexion is also committed to corporate social responsibility, engaging in initiatives that support patient communities and promote access to healthcare. The company believes in the importance of collaboration, working closely with healthcare professionals, patients, and advocacy groups to drive progress in rare disease treatment.

As part of its vision, Alexion aims to redefine the standard of care for patients with rare diseases, continuously seeking new ways to innovate and improve outcomes. The company’s dedication to patients is reflected in its mission to transform the lives of those affected by these challenging conditions.

Key Highlights:

• Founded: 1992
• Headquarters: United Kingdom
• Core Focus: Rare diseases and complement inhibition
• Flagship Product: Soliris
• Global Presence: North America, Europe, Asia